- The key vendors in the Global Psoriasis Therapeutics Market 2015-2019 are AbbVie Inc., Amgen Inc., Janssen Pharmaceuticals Inc. and Pfizer Inc.
London, 23 December 2014: TechNavio, an independent tech-focused global research firm, has announced the publication of its market research report on the Global Psoriasis Therapeutics Market 2015-2019. The dominance of the market by biologics is one major trend in this market. It is expected to be a preferred choice of treatment among patients, their families, and the medical community. This, in turn, is expected to raise the number of treatment-seeking patients, which is expected to result in an increase in the overall consumption of medicines. The Global Psoriasis Therapeutics market is expected to grow at a CAGR of 9.95 percent during the period 2014-2019.
“Vendors in the Global Psoriasis Therapeutics market are continuing trials with many other small molecule drugs and biologics, which are mostly in phase II and phase III trials,” says Faisal Ghaus, Vice President of TechNavio Research.
“The expected launch of pipeline drugs for the treatment of psoriasis is expected to boost the growth of the market. Some of the potential drug candidates that are expected to be launched during the forecast period are Briakinumab, Secukinumab, Brodalumab, and Ixekizumab.”
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
